Xencor (NASDAQ:XNCR) Trading 9.3% Higher - Time to Buy?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) shares were up 9.3% during trading on Monday . The company traded as high as $10.76 and last traded at $10.61. Approximately 105,628 shares were traded during trading, a decline of 85% from the average daily volume of 688,287 shares. The stock had previously closed at $9.70.

Analyst Ratings Changes

A number of equities research analysts have issued reports on XNCR shares. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company cut their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Finally, William Blair initiated coverage on shares of Xencor in a research report on Monday. They issued an "outperform" rating for the company. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Xencor currently has an average rating of "Moderate Buy" and an average price target of $33.86.

Xencor Stock Performance

The company has a fifty day moving average price of $11.88 and a two-hundred day moving average price of $18.49. The firm has a market cap of $744.08 million, a price-to-earnings ratio of -3.32 and a beta of 0.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. The company had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, equities research analysts expect that Xencor, Inc. will post -3.68 EPS for the current year.

Hedge Funds Weigh In On Xencor

Institutional investors have recently bought and sold shares of the stock. Diversified Trust Co purchased a new position in shares of Xencor in the first quarter worth approximately $172,000. Exchange Traded Concepts LLC grew its position in Xencor by 23.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 9,814 shares of the biopharmaceutical company's stock worth $104,000 after purchasing an additional 1,896 shares in the last quarter. GAMMA Investing LLC raised its stake in Xencor by 348.5% during the 1st quarter. GAMMA Investing LLC now owns 9,629 shares of the biopharmaceutical company's stock valued at $102,000 after purchasing an additional 7,482 shares during the period. Wellington Management Group LLP purchased a new stake in shares of Xencor in the fourth quarter valued at $632,000. Finally, California State Teachers Retirement System boosted its position in shares of Xencor by 12.1% in the fourth quarter. California State Teachers Retirement System now owns 59,130 shares of the biopharmaceutical company's stock worth $1,359,000 after buying an additional 6,376 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.